Study of VTD in Waldenstrom's Macroglobulinemia
This study is a phase 2, single-arm, open-label, multi-institutional trial to evaluate the efficacy of combination therapy of bortezomib, thalidomide, and dexamethasone in patients with newly diagnosed Waldenstrom's macroglobulinemia and lymphoplasmacytic lymphoma.
Waldenstrom Macroglobulinemia|Lymphoplasmacytic Lymphoma
DRUG: Bortezomib
Overall response rate, Overall response rate as per Lugano criteria, at 3 years
Progression-free survival, Time from enrollment to disease progression or death from any cause, at 3 years|Overall survival, Time from enrollment to death from any cause, at 3 years
This study is a phase 2, single-arm, open-label, multi-institutional trial to evaluate the efficacy of combination therapy of bortezomib, thalidomide, and dexamethasone in patients with newly diagnosed Waldenstrom's macroglobulinemia and lymphoplasmacytic lymphoma.